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Abstract
Given the high morbidity for mother and fetus associated with malaria in pregnancy, safe
and efficacious drugs are needed for treatment. Artemisinin derivatives are the most effec-
tive antimalarials, but are associated with teratogenic and embryotoxic effects in animal
models when used in early pregnancy. However, several organ systems are still under
development later in pregnancy. We conducted a systematic review and meta-analysis of
the occurrence of adverse pregnancy outcomes among women treated with artemisinins
monotherapy or as artemisinin-based combination therapy during the 2nd or 3rd trimesters
relative to pregnant women who received non-artemisinin antimalarials or none at all.
Pooled odds ratio (POR) were calculated using Mantel-Haenszel fixed effects model with a
0.5 continuity correction for zero events. Eligible studies were identified through Medline,
Embase, and the Malaria in Pregnancy Consortium Library. Twenty studies (11 cohort stud-
ies and 9 randomized controlled trials) contributed to the analysis, with 3,707 women
receiving an artemisinin, 1,951 a non-artemisinin antimalarial, and 13,714 no antimalarial.
The PORs (95% confidence interval (CI)) for stillbirth, fetal loss, and congenital anomalies
when comparing artemisinin versus quinine were 0.49 (95% CI 0.24–0.97, I2 = 0%, 3 stud-
ies); 0.58 (95% CI 0.31–1.16, I2 = 0%, 6 studies); and 1.00 (95% CI 0.27–3.75, I2 = 0%,
3 studies), respectively. The PORs comparing artemisinin users to pregnant women who
received no antimalarial were 1.13 (95% CI 0.77–1.66, I2 = 86.7%, 3 studies); 1.10 (95% CI
0.79–1.54, I2 = 0%, 4 studies); and 0.79 (95% CI 0.37–1.67, I2 = 0%, 3 studies) for miscar-
riage, stillbirth and congenital anomalies respectively. Treatment with artemisinin in 2nd and
3rd trimester was not associated with increased risks of congenital malformations or miscar-
riage and may be was associated with a reduced risk of stillbirths compared to quinine. This
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Introduction
Given the highmorbidity and mortality associatedwith malaria in pregnancy, safe and effective
drugs are needed for treatment and prevention [1]. However, there is limited information on
the safety profile of most antimalarials when used during pregnancy, in part because few clini-
cal trials enroll pregnant women and there are few examples of systematic approaches to preg-
nancy pharmacovigilance [2,3].
The World Health Organization (WHO) currently recommends the use of artemisinin-
based combination therapy (ACT) for the treatment of uncomplicated malaria in adults, chil-
dren and in pregnant women in the 2nd or 3rd trimester [4]. Seven days of quinine with clinda-
mycin is recommended for uncomplicated malaria in the first trimester of pregnancy [5]. The
reports from relatively small observational studies and randomized controlled trials (RCTs)
have not identified an increased risk of miscarriage or stillbirth after receipt of artemisinins
during pregnancy, compared to women receiving non-artemisinin antimalarials or to pregnant
women who did not receive any antimalarials [6–12].
TheWHO recommends the use of ACTs in the first trimester if this is the only treatment
immediately available, or if treatment with 7-day quinine plus clindamycin fails or if there is
uncertainty about adherence to a 7-day treatment [13]. Studies of rats, rabbits, and primates
have reported the artemisinin class of antimalarial drugs to be embryotoxic and teratogenic
[2]. These animal studies suggest that the etiologically relevant time period for exposure in
humans is within the first trimester. Several organs are still under development in the 2nd tri-
mester and therefore sensitive to teratogens, including the uterus (18 weeks), brain (until
birth), eyes (24–36 weeks), and ears (18 weeks) [14], although animal data did not observe
these types of anomalies after artemisinin exposure [15]. Nevertheless, animal data do not
always mirror the effects observed in humans.
We conducted a systematic review and meta-analysis examining the risk of adverse preg-
nancy outcomes associated with 2nd or 3rd trimester use of an artemisinin, compared with the
experience of pregnant women treated with other antimalarial therapies and pregnant women
without malaria and therefore no exposure to an antimalarial.
Methods
This analysis was completed in accordance with the PRISMA guidelines (S1 and S2 Figs) [16].
The safety outcomes assessed were miscarriage (<28 weeks), stillbirth (>/ = 28 weeks), fetal
loss (composite of miscarriage or stillbirth), and congenital anomalies.
Search Strategy
We conducted an electronic search of Medline, Embase, and the Malaria in Pregnancy Library
as of January 12, 2015, and the Medline search was updated on June 15, 2015, using the Patient,
Intervention, Comparator, Outcome, Timing and Setting (PICOTS) framework (S1 Fig)
[17,18]. We also searched 'gray literature' databases, conference abstracts and manually
reviewed reference lists of selected publications.
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Inclusion/exclusion criteria
Studies fulfilling the following criteria were eligible for inclusion: prospective cohort studies or
RCTs enrolling women of child bearing age (WOCBA) or pregnant women of any gestational
age who received an artemisinin in the 2nd or 3rd trimester either as a monotherapy or as an
ACT for the treatment of P. falciparum, P. vivax or mixed infections, and with information
available on fetal loss and/or congenital anomalies, and information on timing of exposure in
pregnancy (e.g. 2nd or 3rd trimester). Study exclusion criteria were case-control studies and
cross-sectional surveys, studies not involving artemisinins treatment, studies reporting only 1st
trimester artemisinin exposures, and studies that did not report pregnancy outcomes. In stud-
ies that reported exposures in both first trimester and 2nd or 3rd trimester, the pregnancies with
first trimester exposures were excluded from the analysis.
Data Extraction
Two reviewers (SK and AE) independently screened titles and abstracts of all citations to iden-
tify potentially eligible studies (first screen). The second screen consisted of full-text review of
studies selected by either reviewer in the first screen with agreement required for final study eli-
gibility and inclusion in the systematic review. Any disagreements on study inclusion were
resolved by discussions between the reviewers. The two reviewers independently extracted data
using a standardized form and resolved any discrepancies by consensus. The primary data
abstracted included number, type, and timing of antimalarial drug exposures; patient charac-
teristics including age, parity, parasitemia level, and HIV prevalence; and pregnancy outcomes
including the number of miscarriages, stillbirths, and congenital anomalies reported by expo-
sure. In addition we created a composite outcome of “any fetal loss” which combined any mis-
carriage or stillbirth for studies that did not clearly delineate the number of exposures in the
2nd and 3rd trimester.
Bias assessment
To assess the possibility of bias we applied the CochraneCollaboration’s tool to score RCT
studies as having high, low, or unclear risk of bias [19]. The Newcastle Ottawa scale was used
to evaluate cohort studies for selection bias, comparability, and assessment of the outcome
[20].
Exposure groups
The main exposure group of interest consisted of pregnant women who received artemisinin
treatment in the 2nd or 3rd trimester. The comparison groups consisted of the following other
exposure groups 1) treatment with oral quinine in the 2nd or 3rd trimester, 2) treatment with
SP (for case-management) in the 2nd or 3rd trimester, 3) treatment with ‘other antimalarials’
(any non-artemisinin) in the 2nd or 3rd trimester, 4) women who received IPT-SP for preven-
tion of malaria, and 5) pregnancies which did not receive an antimalarial drug in the 2nd or 3rd
trimester (i.e. because they did not have clinical malaria).
Outcome definitions
Miscarriage was defined as pregnancy loss of<28 weeks of gestation and stillbirth as preg-
nancy loss of28 weeks. This cut-off was chosen because the majority of the studies were con-
ducted in resource-limited settings without access to neonatal intensive care. Fetal loss was
defined as miscarriage or stillbirth. Studies that reportedmiscarriages but did not report the
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number of exposures occurring before 28 weeks of gestation or studies that reportedmiscar-
riages and stillbirths using different definitions, were included in the analyses of any fetal loss.
We defined congenital malformation as any major or minor anomaly. We included all
reported congenital anomalies in the analysis because of inconsistencies in the definition of
major congenital malformations. We grouped congenital anomalies by organ system according
to classifications developed by the Antiretroviral Pregnancy Registry [21].
Statistical Methods
Comparing risk estimates between exposure groups: To compare the risk between exposure
groups, crude pooled odds ratios (PORs) and pooled risk differences (PRDs) were obtained
from the reported count data. Our primarymeasure of association was a POR, but for analyses
in which studies reported zero outcomes in both comparison arms, we conducted PRDmodels
to allow all data to contribute to the model.We used a 0.5 continuity correctionwith a Mantel-
Haenszel fixed effectsmodel to correct for zero event cells [22]. As sensitivity analysis, we used
random effectsmodel with DerSimonian-Lairdweighting and Peto Method with a 0.5 continu-
ity correction, and Mantel-Haenzel fixed effects with continuity corrections of 0.01 and 0.69
[22].
As per the CochraneCollaboration guidelines, I2 values>75% were considered indicative of
considerable heterogeneity [23]. We conducted stratified analyses by study type, geographic
location, and comparison drug exposures, as well as bias level where possible (i.e. low, moder-
ate, high; S1 and S2 Tables).
Results
A total of 944 articles or reports were identified. After removal of duplications and review of
titles, a total of 309 abstracts were reviewed and 20 studies (11 cohort studies and 9 RCTs, 10
from Africa and 10 from Asia) met the inclusion criteria and were included in at least one of
the analyses (Fig 1). Six studies did not include comparisons with other non-artemisinins and
were used only descriptively and not included in the pooledORs, with the remaining 14 studies
providing data for the pooledORs. Twelve studies did not report if exposures occurred in the
second or third trimester, and therefore were excluded from the analysis of miscarriage. The
search did not identify any studies of artemisinins used for intermittent preventive treatment
(IPT) of malaria during pregnancy that provided necessary data on pregnancy outcomes.
A total of 3,646 women in these 20 studies received an artemisinin during the 2nd or 3rd tri-
mester of pregnancy (Tables 1 and 2). The most common exposures were: artemether-lume-
fantrine (AL) (N = 2,000), dihydroartemisinin piperaquine (DP) (N = 328), monotherapy with
any artemisinin derivative including artemether and artesunate (N = 225), artesunate sulfadox-
ine-pyrimethamine (AS-SP) (N = 197), artesunate-mefloquine (AS-MQ) (N = 94), artesunate-
amodiaquine (AS-AQ) (N = 83), and artesunate atovaquone-proguanil AAP (N = 39). One
study reported 412 women receiving artesunate or artemether alone or in combination with
MQ, clindamycin, atovaquone-proquanil (AP), artesunate iv, or AL but specific numbers were
not reported by drug due to multiple treatments per patient [12]. There were 1,951 women
who received other antimalarials in the 2nd or 3rd trimester including: chlorproguanil-dapsone
(CD) (N = 81); chloroquine-SP (N = 24); mefloquinemonotherapy (N = 36); quinine
(N = 661); SP (for case-management) (N = 456); SP-AQ (N = 80), and SP-azithromycin
(AZM) (N = 47), and for prevention IPTp-SP (N = 566). In these 20 studies, an additional
13,714 pregnant women reported no exposure to antimalarials and no recorded illness of
malaria. Two studies with a no antimalarial comparison group were conducted in regions in
sub-Saharan Africa where the risk of malaria is high [7,24]. The majority (n = 8194) of the
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women who were not exposed to an antimalarial were from one site in Thailand with a low risk
of malaria where all patients were screenedweekly for malaria, and therefore no IPTp-SP was
provided [12].
Ten studies reported data on presence of fever at enrollment, and 12 studies reported enroll-
ment parasitemia (S3 Table). The mean gestational age at enrollment ranged from 21 weeks to
Fig 1. PRISMA flow diagram for search results June 15, 2015.
doi:10.1371/journal.pone.0164963.g001
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Table 1. Description of cohort studies identified in the systematic review and included in the meta-analysis.
Study Location and time
period
Study Population ACT Exposures Comparator
Exposures
2-3rd Trimester
Outcomes
Adam, 2004 [25] Sudan October
1997-February
2001
Pregnant women who presented with
symptoms of P. falciparum malaria and
had confirmed malaria parasites who
were treated with quinine and returned to
the hospital with recurrent malaria
symptoms and parasite detected within
three weeks. Mean age 27.1 years
Art im = 28
1st trim = 1/28
2nd trim = 12/28
3rd trim = 15/28
N/A Miscarriage = 0/12
Stillbirth = 0/27
CA = 0/27
Adam, 2006 [26] Sudan September
2004-March 2005
Pregnant women with uncomplicated P.
falciparum malaria. Mean age 29.4 (s.d.
4.3) years
AS+SP = 32
2nd trim = 10/32
3rd trim = 22/32
N/A Miscarriage = 0/10
Stillbirth = 0/32
CA = 0/32
Deen, 2001 [24] Gambia March,
2000
All women of reproductive age (15–44
years) residing in the 42 study villages.
Villages were part of a mass drug
administration campaign. Pregnant
women exposed to Mass drug
administration were followed.
AS+SP = 287
1st trim = 77/287
2nd trim = 90/287
3rd trim = 28/287
Placebo = 40
No exp. = 132
Miscarriage:
AS-SP = 0/90
Comm. +Placebo =
2/132
Stillbirth:
AS-SP = 11/287
Comm.
+Placebo = 6/172
CA:
AS+SP = 6/287
Comm.
+Placebo = 2/172
Manyando, 2010
[8]
Zambia October
2004-July 2008
Pregnant women attending antenatal
clinic who were grouped based on the
drug used to treat their last episode of
malaria. Mean age NR.
AL = 495
1st trim = 159
2nd trim = 169
3rd trim = 162
SP = 506
1st trim = 125
2nd trim = 205
3rd trim = 176
Miscarriage:
AL = 0/169
SP = 5/205
Stillbirth:
AL = 9/473
SP = 13/478
CA:
AL = 29/449
SP = 18/444
McGready, 2001
[12]
Thailand 1986–
2001
Pregnant women who had microscopy
confirmed P. falciparum or mixed P.
falciparum and P. vivax infections. Mean
age 24.8 (s.d. 6.4) years
Artesunate or artemether
alone or in combination with
MQ, C AP, or artesunate iv, or
AL N = 461
1st trim = 40
2nd trim = 201
3rd trim = 211
No exp. = 8154 Miscarriage:
Artemisinin = 20/
201
Comm. = 1003/
8154
Stillbirth:
Artemisinin = 7/386
Comm. = 114/7058
CA:
Artemisinin = 3/386
Comm. = 56/3707
*McGready,
1999 [27]
Thailand 1991–
1996
Pregnant women in camps for refugees
with uncomplicated, multi-drug resistant
P. falciparum malaria.
AS = 61
2-3rd trim = 61 *study reports
outcomes for 78 exposures
Q = 72
2-3rd trim = 72
MQ = 36
2-3rd trim = 36
Stillbirth:
AS = 2/78
MQ or Q = 8/322
Any Fetal Loss:
AS = 3/78
Q+MQ = 16/322
CA:
AS = 0/73
MQ or Q = 4/322
Mosha, 2014[28] Tanzania April-
September 2012
2-3rd trimester pregnant and non-
pregnant women with diagnosed
uncomplicated malaria. P. falciparum
detected by microscopy and hemoglobin
level >/ = 7g/dl. Median age 25, range 18–
41 years
AL = 55
2nd trim = 17
3rd trim = 16
Not pregnant AL N = 22
N/A Miscarriage: 0/17
Stillbirth: 0/33
CA: 0/33
(Continued )
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38 weeks across the studies. Only three studies reported data on HIV status, preventing stratifi-
cation by HIV status [8,33,36]. Further details about the characteristics of included women can
be found in S3 Table.
Miscarriage
Eight studies reported data on late miscarriages after receipt of an artemisinin in the second tri-
mester, but only four studies reported comparisons with pregnant women who did not receive
artemisinins and there were no studies with a quinine arm. A total of 34 miscarriages were
reported among 939 women given artemisinins, including data from 5 studies reporting no
miscarriages among 304 exposures.
Table 1. (Continued)
Study Location and time
period
Study Population ACT Exposures Comparator
Exposures
2-3rd Trimester
Outcomes
Rulisa, 2012[7] Rwanda June
2007-July 2009
Pregnant women age 18+ treated with AL
after diagnosis of simple P. falciparum
malaria based on blood smear or clinical
symptoms. Controls were pregnant
women with no malaria. Age range 16–
48.
AL = 1072
2nd trim = 434
3rd trim = 542
No exp. = 978 Miscarriage:
AL 14/434
No antimalarial = 4/
978
Stillbirth:
AL = 31/1072
No
antimalarial = 23/
978
CA:
AL = 3/1072
No antimalarial-3/
978
Poespoprodjo,
2014 [29]
Indonesia April
2004-June 2009
All pregnant women and newborn infants
admitted to maternity ward screened for
malaria.
DP = 336
1st trim = 8
2-3rd trim = 328
DP+ivArt = 77
1st trim = 10
2-3rd trim = 67
Quinine = 347
iv Q 1st
trim = 50
2-3rd
trim = 259
CQ+SP = 24
2-3rd trim = 24
No exp. = 4408
Stillbirth:
DP = 9/328
DP+ivART = 2/67
CQ+SP = 0/24
Q = 16/259
Community = 134/
4408
Wang, 1989 [30] China 1976–1980 Pregnant women with malaria with typical
symptoms and signs; Plasmodium found
in thick blood smear with a density over
500 mm3 and antimalarial had not been
administered or with a known grade III
chloroquine resistance. Mean age 25.8
(s.d. 4.1) years
Artemisinin in oil = 2
2nd trim = 2
Artemether = 4
2nd trim = 4
N/A Miscarriage:
Art oil = 0/2
Art = 0/4
Stillbirth:
Art oil = 0/2
Art = 0/4
CA:
Art oil = 0/2
Art = 0/4
^Nakelembe,
2012 [31]
Uganda and
Burkina Faso
HIV negative women in the 2nd or 3rd
trimester who were screened for malaria
during normal IPT schedule and given AL
if positive or SP if negative and followed
through pregnancy
AL = 287
2-3rd trim = 287
IPT with
SP = 566
2-3rd trim = 566
Stillbirth:
AL = 3/287
IPT SP only = 7/566
*Pregnancy outcomes were reported for 78 artemisinin exposures, and 322 combined MQ and Q exposures. These ACT exposures are also included in the
McGready 2001 cohort study with different comparison group (no antimalarial drug exposures).
^ Data provided by the authors. Trim trimester; ART im: artemether intramuscular; AS: artesunate; SP: sulfadoxine pyrimethamine; AL: artemether
lumefantrine; CA: congenital anomal; MQ: mefloquine; C: Clindamycin; CD: chlorproguanal-dapsone; iv: intravenous; AP: atovaquone proquanil; Q:
quinine; AS7: artesunate 7 days; CQ: chloroquine; AQ: amodiaquine; DP: dihydroartemisinin-piperaquine; IPT: intermittent preventative therapy; MDA:
Mass drug administration; ANC: antenatal care; No exp: no exposure to antimalarials for treatment.
doi:10.1371/journal.pone.0164963.t001
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Table 2. Description of RCT studies identified in the systematic review and included in the meta-analysis.
Study Location and time
period
Study Population ACT
Exposures
Comparison
Exposures
2-3rd Trimester
Outcomes
Bounyasong,
2001 [32]
Thailand January
1995-December 1998
Pregnant women with P. falciparum, not more than 4%
parasitized red cells, gestational age at least 28 weeks
estimated by ultrasound.
AS+MQ = 28
2-3rd
trim = 28
Q = 29
2-3rd trim = 29
Any Fetal Loss:
AS-MQ = 0/28
Q = 0/29
CA
AS-MQ = 0/28
Q = 0/29
Kalilani, 2007
[33]
Malawi September
2003-September 2004
Pregnant women (EGA 14–26 weeks) between 15 and
49 years old, with peripheral P. falciparum parasitemia;
method of measuring gestational age not described.
Median age 20 (range 17–24).
AS+SP = 47
2-3rd
trim = 47/47
SP = 47
2-3rd trim = 47
SP+AZM = 47
2-3rd trim = 47
Stillbirth:
AS-SP = 4/38
SP = 1/38
SP+AZM = 0/42
Any fetal loss:
AS-SP = 4/38
SP = 0/38
SP+AZM = 4/42
CA:
AS-SP = 0/38
SP = 0/38
SP-AZM = 0/42
McGready,
2000 [11]
Thailand October
1995-July 1997
Pregnant women in 2nd or 3rd trimester, estimated by
fundal height seen at ANC who had microscopy
confirmed uncomplicated P. falciparum infection
AS-MQ = 66
2-3rd
trim = 66
Q = 42
2-3rd trim = 42
Any Fetal Loss:
AS-MQ = 2/66
Q = 0/42
CA:
AS-MQ = 0/66
Q = 0/42
McGready,
2001 [34]
Thailand October
1997-January 2000
Pregnant women in 2nd or 3rd trimester estimated by
fundal height seen at ANCs who had microscopy
confirmed P. falciparum infections. Age range 15–41
years
AS7 N = 64
2-3rd
trim = 64
Q+C N = 65
2-3rd trim = 65
Stillbirth:
AS7 = 1/64
Q+C = 1/65
Any Fetal Loss:
Art = 1/64
Q+C = 1/65
CA:
Art = 0/64
Q+C = 1/65
McGready,
2005 [35]
Thailand December
2001-July 2003
Pregnant women with first episode of P. falciparum or
mixed infection (P. vivax), 14–31 weeks gestation
estimated by ultrasound or fundal height, Ht > = 20%.
Mean age 26 (s.d. 7) years
AAP N = 39
2-3rd
trim = 39
Q N = 42
2-3rd trim = 42
Any Fetal Loss:
AAP = 0/34
Q = 0/38
CA:
AAP = 2/34
Q = 1/38
McGready,
2008 [10]
Thailand April
2005-August 2006
Patients with acute P. falciparum malaria in 2nd or 3rd
trimester estimated by ultrasound. Originally only
allowed 2nd infection in pregnancy (already failed
quinine), but later widened to allow first infections in
pregnancy. Age range 14–44 Years
AL N = 125
2-3rd
trim = 125
AS7 N = 128
2-3rd
trim = 128
Stillbirth:
AL = 1/117
AS7 = 1/120
Any Fetal Loss:
AL = 1/117
AS7 = 2/120
CA:
AL = 3/117
AS7 = 4/120
Mutabingwa,
2009 [36]
Tanzania January
2004-September 2006
Pregnancy with either a positive blood smear for P.
falciparum with at least 800 parasites/μL in an
asymptomatic woman or any of the following symptoms
within 2 days prior to consultation: history of fever,
headache, vomiting, chills/rigors and/or any of the
following signs: temperature37.5 & <39.5˚C, Hb7
and <9 g/dl) with P. falciparum parasitemia at any
density. All cases were between 14–34 weeks
gestation defined by presence of fetal heartbeat.
Median age 21 years
AS-AQ = 83
2-3rd
trim = 83
SP = 28
2-3rd trim = 28
SP-AQ = 80
2-3rd trim = 80
CD = 81
2-3rd trim = 81
Any Fetal Loss:
AS-AQ = 4/83
SP-AQ = 1/80
SP = 0/28
CD = 1/81
CA:*
AS+AQ = 3/83
SP = 3/28
CD = 7/81
SP+AQ = 8/80
(Continued )
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Comparison to SP for treatment. Only one study compared use of artemisinins to use of
SP, with zero miscarriages among 169 ACTs exposures and 5 miscarriages among 205 SP
exposures.
Comparison to no antimalarial drug exposure. Three studies compared artemisinin
users to women who did not receive an antimalarial drug. There were 34 miscarriages among
725 women who received an artemisinin, and 1009 miscarriages among 9264 women who
received no antimalarials and therefore were unlikely to have malaria (POR = 1.13, 95% CI
0.77–1.66, I2 = 86.7%, 3 studies) (Fig 2).
Stillbirth
Sixteen studies reported a total of 83 stillbirths among 3,595 women who received an artemisi-
nin in the 2nd or 3rd trimester.
Comparison to Quinine. In studies with a quinine comparison arm, there were 14 still-
births among 603 women who received an artemisinin and 20 stillbirths among 461 women
who received quinine (POR 0.49, 95% CI 0.24–0.97, I2 = 0%, 3 studies) (Fig 3).
Comparison to SP treatment. In the two studies comparing use of artemisinins to SP for
case-management, there were 13 stillbirths among 511 women who received an artemisinin,
and 14 stillbirths among 516 women who received SP (POR 0.93, 95% CI 0.43–2.01, I2 = 56%,
2 studies).
Comparison to other antimalarials for treatment. Receipt of an artemisinin was not
associated with a clear increase in the risk of stillbirth compared to receipt of SP combinations
(POR 3.47, 95% CI 0.46–26.03 I2 = 100%, 2 studies); these results were based on only two stud-
ies with considerable evidence of heterogeneity. Receipt of artemisinin compared to meflo-
quine and/or quinine for the treatment of malaria was not associated with an increased risk of
stillbirthOR 1.03 (95% CI 0.21–4.96).
Table 2. (Continued)
Study Location and time
period
Study Population ACT
Exposures
Comparison
Exposures
2-3rd Trimester
Outcomes
Piola, 2010 [6] Uganda October
2006-May 2009
Women with viable pregnancy with an estimated
gestation of13 weeks determined by ultrasound or
LMP and malaria infection detected by microscopy (P.
falciparum mixed or monoinfection). SP may have been
used for prevention before entry to the study and some
inadvertently when entered.
AL = 152
2-3rd
trim = 152
Q = 152
2-3rdtrim = 152
Stillbirth:
AL = 2/144
Q = 3/137
Any fetal loss:
AL = 5/144
Q = 7/137
CA:
AL = 3/144
Q = 2/137
Sowunmi, 1998
[37]
Nigeria January
1994-March 1997
All patients referred to University College Hospital with
persistent P. falciparum parasitemia and acute
uncomplicated malaria after failure of supervised
therapy with standard regimen of chloroquine or after a
single dose of SP or both CQ and SP. Oral fluid
intolerance, no history of allergy to known antimalarial
drugs, 2nd or 3rd trimester determined by ultrasound
Art+MQ = 23
2-3rd
trim = 23
Art im = 22
2-3rd
trim = 22
Stillbirth:
Art+MQ = 0/23
Art im = 0/22
Any fetal loss:
Art+MQ = 0/23
Art im = 0/22
CA:
Art+MQ = 0/23
Art im = 0/22
*Only minor CA. Trim: trimester; ART im: artemether intramuscular; AS: artesunate; AZM: azithromycin; SP: sulfadoxine pyrimethamine; AL: artemether
lumefantrine; CA: congenital anomaly; C: Clindamycin; MQ: mefloquine; CD: chlorproguanal-dapsone; iv: intravenous; AP: atovaquone proquanil; Q:
quinine; AS7: artesunate 7 days; CQ: chloroquine; AQ: amodiaquine; DP: dihydroartemisinin-piperaquine; IPT: intermittent preventative therapy.
doi:10.1371/journal.pone.0164963.t002
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Comparison to IPT-SP. Only one study compared women who received artemisinins for
treatment to women who only received IPT-SP. There was no increased risk of stillbirth after
receipt of an artemisinin compared to women who received only IPT-SP, OR = 0.84 (95% CI
0.22–3.29).
Comparison to no antimalarial drug exposure. In the studies that compared use of an
artemisinin to no exposure to antimalarials, there were 60 stillbirths among 2131 women who
received an artemisinin, and 277 among 12,622 women who received no antimalarials (POR
1.10, 95% CI 0.79–1.54, I2 = 0%, 4 studies).
Any Fetal Loss
In twelve studies that did not specify if exposures occurred in the 2nd or 3rd trimester, there
were 38 fetal losses among 1505 women who received an artemisinin in the 2 or 3rd trimester.
Comparison to Quinine. In the 6 studies with a quinine arm, there were 19 fetal loses
among 731 women who received artemisinins, and there were 24 fetal losses among 559 qui-
nine exposures (POR = 0.58, 95% CI 0.31–1.06, I2 = 0%, 6 studies) (Fig 4).
Comparison to SP for treatment. In the two studies with an SP arm, there were 9 fetal
losses among 121 women who received an artemisinin and there were zero fetal losses among
66 women who received SP for treatment. (POR 5.86, 95% CI 0.73–46.88, I2 = 0%, 2 studies).
Fig 2. Pooled odds ratio for miscarriage after 2nd trimester exposures to artemisinins stratified by comparison group. *McGready 2001
reported multiple types of artemisinin exposures that were combined for this analysis (12). ART artemisinins, AL artemether-lumefantrine, AS-SP
artesunate sulfadoxine pyrimethamine, SP sulfadoxine pyrimethamine, No exp. No exposure to antimalarials.
doi:10.1371/journal.pone.0164963.g002
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Comparison to other non-artemisinin antimalarials for treatment. Receipt of artemisi-
nins in the 2nd or 3rd trimester was not associated with an increased risk of fetal loss compared
to SP combinations or other antimalarials (POR 1.71, 95% CI 0.57–5.07, I2 = 0%, 3 studies, and
POR 1.70 95% CI 0.70–4.15, I2 = 0%, 2 studies, respectively).
Comparison to IPT-SP. Only one study compared artemisinin to IPT-SP. There was no
increased risk of fetal loss among women who received an artemisinin for treatment compared
to women who only received IPT-SP (OR = 0.84, 95% CI 0.22–3.29).
Fig 3. Pooled odds ratio for stillbirth after 2-3rd trimester exposures to artemisinins compared to other drugs. *McGready 2001 reported
multiple types of artemisinin exposures that were combined for this analysis and reported as ACT (12). ^McGready 1999 MQ or Q exposures
include patients given MQ, Q, or both (33). ART: artesunate, AL: artemether-lumefantrine, AAP: artesunate atovaquone proguanil, AS-AQ:
artesunate-amodiaquine, Q: quinine, Q+C: quinine+clindamycin, SP: sulfadoxine pyrimethamine, AQ: amodiaquine, SP+CQ: sulfadoxine
pyrimethamine chloroquine, MQ: mefloquine, SP-AZM: sulfadoxine pyrimethamine azithromycin, CD: chlorproguanal-dapsone, IPT: intermittent
preventative treatment, RCT: randomized controlled trial, ACT: artemisinin combination therapy, No exp. no exposure to antimalarials.
doi:10.1371/journal.pone.0164963.g003
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Comparison to no antimalarial drug exposure. Based on the results of a single study,
there was no increased risk of fetal loss among women who received an artemisinin compared
to women who received no antimalarial drugs (OR = 0.93, 95% CI 0.50–1.74).
Congenital Anomalies
Thirteen studies reported a total of 55 congenital anomalies among 2,807 exposures to artemi-
sinins in the 2nd or 3rd trimesters.
Fig 4. Pooled Odds ratio for fetal loss after 2-3rd trimester exposures to artemisinins stratified by comparison group. *McGready 2001
reported multiple types of artemisinin exposures that were combined for this analysis and reported as ACTs (12). ^McGready 1999 MQ or Q
exposures include patients given MQ, Q, or both (33). ART: artesunate, AS-MQ: artesunate mefloquine, AL: artemether-lumefantrine, DP:
dihydroartemisinin-piperaquine, AAP: artesunate atovaquone proguanil, AS-SP: artesunate sulfadoxine pyrimethamine, AS-AQ: artesunate-
amodiaquine, Q: quinine, Q+C: quinine+clindamycin, SP: sulfadoxine pyrimethamine, AQ: amodiaquine, SP+CQ: sulfadoxine pyrimethamine
chloroquine, MQ: mefloquine, SP-AZM: sulfadoxine pyrimethamine azithromycin, CD: chlorproguanal-dapsone, IPT: intermittent preventative
treatment, RCT: randomized controlled trial, ACT: artemisinin combination therapy, No exp. No exposure to antimalarials.
doi:10.1371/journal.pone.0164963.g004
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Comparison to quinine. There were 4 congenital anomalies among infants born to 242
women who received an artemisinin and 4 congenital anomalies among 239 women who
received quinine (POR = 1.00, 95% CI 0.27–3.75, I2 = 0%, 3 studies) (Fig 5).
Comparison to SP for treatment. In the two studies comparing artemisinins to SP, there
were 32 congenital anomalies among 532 women who received an artemisinin and 21 congeni-
tal anomalies among 472 women who received SP (POR = 1.37, 95% CI 0.78–2.39, I2 = 70.3%,
2 studies).
Comparison to no antimalarial drug exposure. In studies with women who were not
exposed to antimalarials in pregnancy, there were 12 congenital anomalies among 1745
Fig 5. Pooled odds ratio for congenital anomalies after 2-3rd trimester exposures to artemisinins stratified by comparison group.
*McGready 2001 reported multiple types of artemisinin exposures that were combined for this analysis and reported as ACTs (12). ART:
artesunate, AL: artemether-lumefantrine, AAP: artesunate- atovaquone proguanil, AS-AQ: artesunate-amodiaquine, Q: quinine, Q+C: quinine
+clindamycin, SP: sulfadoxine pyrimethamine, AQ: amodiaquine, SP+AQ: sulfadoxine pyrimethamine amodiaquine, MQ: mefloquine, CD:
chlorproguanal-dapsone, RCT: randomized controlled trial, ACT: artemisinin combination therapy, No exp. No exposure to antimalarials.
doi:10.1371/journal.pone.0164963.g005
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women who received an artemisinin and 64 congenital anomalies among 4857 women who did
not receive antimalarials in pregnancy (POR 0.79, 95% CI 0.37–1.67, I2 = 0%, 3 studies).
Across the 13 studies reporting data on congenital anomalies, the most common congenital
anomaly reported was umbilical hernia; 21 among infants exposed in utero to ACT during the
2 or 3rd trimester and an additional 12 umbilical hernias reported among 1,113 infants whose
mother used other antimalarials during pregnancy. There were three central nervous system
(CNS) defects among infants exposed to ACTs (anencephaly, hydrocephaly, and hemimega-
loencephaly), but no CNS defects were reported among infants exposed to other antimalarials.
One heart defect was reported among artemisinin exposed infants (acyanotic heart disease),
and none among infants exposed to other antimalarials or no antimalarials in the 2 or 3rd tri-
mester of pregnancy (Table 3). Studies did not routinely report congenital anomalies stratified
by major and minor anomalies; therefore, it was not possible to conduct an analyses of the risk
of any major anomaly. Furthermore, small numbers of events precluded the analysis of con-
genital anomalies stratified by organ system.
Sensitivity Analyses
In order to assess the robustness of our findings for our PORmodels we conducted sensitivity
analyses using different correction factors for zero cells (0.69 and 0.01), and two different pool-
ing techniques, Peto method and random effectsmodels, given that there is a lack of consensus
in the literature on the most appropriate method for modeling rare outcomes [22]. Sensitivity
analyses using different correction factors for zero cells (0.69 and 0.01), and two different pool-
ing techniques, Peto method and random effectsmodels, did not change the overall interpreta-
tion of the analyses, but the results were most sensitive to changes in the correction factor and
not the modeling technique (S4 Table).
Discussion
There was no indication that the risk of late miscarriage was higher in artemisinin recipients
compared to women who received no antimalarials in the 2nd trimester or to SP for treatment,
although the latter comparison included only a single study. There were fewer studies that
compared the risk of late miscarriage, but in 3 studies that compared the risk against women
who received no antimalarials in the 2nd trimester, and in 1 study against women who received
SP for treatment, there was no evidence for an increased risk. The risk of stillbirths in women
treated with artemisinins in the 2nd or 3rd trimester was lower compared to those treated with
oral quinine during the same gestational period.Additionally, there was no increased risk of
stillbirth after receipt of an artemisinin compared to receiving other antimalarials for treat-
ment, IPT-SP only, or receiving no antimalarials. No increased risk was observed for fetal loss
or congenital abnormalities when compared to quinine, SP, other antimalarials, IPT-SP, or to
women who did not receive any antimalarials.
This meta-analysis of over 3500 artemisinin exposures builds upon the existing literature by
including monotherapy and multiple artemisinins combinations therapies and using multiple
comparison groups. PreviousWHO guidelines in 2002 and 2006 were developed based on the
findings for 607 and 1000 2nd or 3rd trimester exposure respectively [38,39]. Specifically, the
results support the findings of a previous meta-analyses of the safety of the artemether-lume-
fantrine (AL) used in pregnancy which showed that AL was not associated with an increased
risk of adverse pregnancy outcomes compared to quinine and SP for treatment [40]. Addition-
ally these results complement recent findings from an updated analysis of first trimester
malaria on the Thailand/Burma border which found no difference in the risk of miscarriage
betweenwomen treated with an artemisinin compared to women treated with quinine [41].
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Table 3. Reported congenital anomalies grouped by organ system and stratified by antimalarial drug exposure during 2-3rd trimester of
pregnancy.
Group and Malformation* No antimalarial exposure ACT Other antimalarial
Central Nervous System (CNS)
Anencephaly 1
Spina bifida 1
Hydrocephalus 1
Unspecified neurologic disorder 1
Hemimegaloencephaly 1
Face and Neck (FACE)
Midline cyst on nose§ 1 1
Unspecified anomaly of ear 1
Unspecified anomaly of eye 1
Nose-small§ 1
Aglossia 1
Obstructive Heart Defects—Left Sided (CV-LT)
Acyanotic heart disease 1
Respiratory System (RES)
Thoracic asymmetry 1
Female Genitalia (G-FEMALE)
Small labia§ 1
Male Genitalia (G-MALE)
Undescended testicles 2
Hernia inguinal 1
Limb Reduction/Addition Defects (LIMB)
Other and unspecified polydactyly 5 6
Hyperextensibility of joint§ 1
Specified or unspecified reduction defect of unspecified limb 1
Other Musculoskeletal Defects (MS-O)
Umbilical hernia§ 21 12
Human tail 1
Unspecified malformation of left foot 1
Skin and Skin Derivatives (SKIN)
Jaundice§ 1
Hyperpigmentation§ 1
Dermal Cyst§ 1
Lanugo§ 1
Haemangioma 1
Unspecified anomaly of skin 2
Chromosome Anomaly (CHROM)
Trisomy 18 1
Trisomy 21 1
Other Organs and Organ Systems (OTHER)
Amniotic banding 1
Alagille’s (genetic) 1
Unspecified anomaly 56 6 23
Total malformations 61 55 45
*No cleft lip and/or palate, conotruncal heart defects, obstructive heart defects—right sided, other heart defects, other circulatory system, upper
gastrointestinal system, lower gastrointestinal system, or renal and urinary system defects were reported.
§Denotes reported congenital anomalies that do not meet the inclusion criteria for the Antiretroviral Pregnancy Registry’s Organ Classification System.
doi:10.1371/journal.pone.0164963.t003
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This study has several limitations. The findings from the 11 cohort studies may be con-
founded by indication due to the non-random administration of treatment. Of the nine studies
that randomized patients to a treatment, five compared an artemisinin to quinine, so con-
founding is unlikely to be an important concern for this comparison. Confounding due to
malaria infection is of particular concern in the studies comparing ACTs for treatment to no
antimalarials, because these studies did not take into account the effect of malaria on poor
pregnancy outcomes. Despite this limitation, we found equivalent risk of adverse pregnancy
outcomes for women who received artemisinins compared to women who received other ther-
apies and no antimalarials. Additionally because of small sample sizes, we were unable to strat-
ify our analyses by potential effectmodifiers such as geography (Asia vs. Africa), which may
account for the observedheterogeneity of our results given the different epidemiology of
malaria in the two regions. Furthermore, only 3 studies reported any data on HIV infection.
Included studies had limited ability to detect an effect on miscarriages because of their recruit-
ment strategies: recruiting women from ANCs can lead to underestimates of the occurrence of
miscarriage because women often present late in the 2nd trimester, and women who have an
early miscarriagewill not present at all, limiting the interpretation of the findings. Additionally,
there may be furthermisclassification of outcome due to limitations of the gestational age
assessment. Finally, there may be heterogeneity in the rigor by which studies assessed outcomes
such as congenital anomalies. Although each study contributing to the analysis was assessed
for bias using either the Cochrane Collaboration Tool or the Newcastle Ottawa Scale, these
tools may not fully capture all sources of bias in the assessment of safety outcomes.
This analysis was limited to artemisinin use for case-management only. Recently two pre-
vention studies which randomized pregnant women to IPT with DP were published [42,43].
As more studies of ACT used for IPT with pregnancy outcomes become available, additional
meta-analyses of safety outcomes may be warranted, especially if they enroll women from first-
trimester.
Despite identifying over 3500 women who received artemisinins in the 2nd or 3rd trimester,
the sample size was too limited to allow the evaluation of the risks of specific congenital anom-
alies. Also, in most studies the ascertainment of anomalies was based only on surface exams
conducted at birth which would not detect congenital anomalies of internal organs or congeni-
tal anomalies of the brain leading to functional deficits. According to the Centers for Disease
Control and Prevention, major congenital anomalies in the U.S. are detected in 5% of children
by age 5, but only 60% of these anomalies are detected at birth [44]. The studies included in the
analyses reported congenital anomalies (major and minor) among 1% of births or less. This
low proportion is likely due to the fact that birth defects such as cardiac defects and those
related to brain development would not be detected by surface exams, and therefore this study
cannot rule out or estimate the risk of these specific anomalies. Given that the brain is still
developing through the 2nd and 3rd trimester, it would be important to assess exposed infants
later in infancy or childhood to rule out an increased risk of these types of defects. In the
review, only three studies followed infants up to one year after birth [10,11,35].
The results of this study build upon the limited data to-date on the safety of ACT used in
pregnancy. These data suggest that the risk of miscarriage and congenital anomalies is similar
among women treated with artemisinins in 2nd or 3rd trimester of pregnancy and women
treated with quinine or other non-artemisinin antimalarials. Furthermore, the risk of stillbirth
was lower compared to quinine recipients, possibly reflecting a higher efficacy of artemisinins
against infection [45]. Though these results were based on few exposures across a limited num-
ber of studies, they support the currentWHO guidelines recommending the use of ACTs for
treatment of malaria in the 2nd or 3rd trimester of pregnancy.
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